| 0 | ℹ |
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
(nejm.org)
|
New England Journal of Medicine 2026-09-24 | #car-t #myeloma #immunotherapy #cytotoxicity |